|Day Low/High||10.41 / 10.73|
|52 Wk Low/High||8.44 / 11.34|
Schering grapples with plant problems, and American Home sees more diet-drug litigation costs.
One analyst studied and ranked big pharmas on how long it takes to get a drug approved by regulators.
An early move to big pharma is likely, then look for some shifting into better biotech.
The FDA won't require more trials of FluMist, so the nasal vaccine should arrive next year.
Chemical stocks are cold as ice, but health care names are on fire.
The drugmaker reported second-quarter net income of 36 cents per share compared to 31 cents per share a year ago.
Despite their recent performance, adding a health care fund to your portfolio can improve returns and reduce risk.
Bristol-Meyers, Pharmacia and American Home all report strong quarters.
Fundamentals remain strong for drug companies, with patent expirations the one worry.
Lord, Abbett's Robert G. Morris sees the S&P rising 21% in the coming months.
Johnson & Johnson and Merck are two of the Dow's few losers today.
It's been a tough year so far for the sector, but here are some smart bets.
Investors bid up the stock after the company adds once more to its diet-drug litigation reserve.
If you are long Philip Morris, the utilities or drug stocks, listen up.
With so many sectors sparkling, fewer stocks are hammered at every selloff, a nice holiday gift.
The drugmaker has been plagued by recalls and lawsuits, but its stock has jumped as tech swoons.
Different kinds of investors need different advice on this group. Cramer can speak to them all.
The company says no patients were affected by the recall of its top-selling drug, a hormone-replacement therapy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.